SCHEMBL3407261

SCHEMBL3407261

c1ccc(C2(N3CCC3)CCCCC2)cc1

nearest known ligand 0.92

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 5/20 0.92
GRIN2A Q12879 5/20 0.92
GRIN2B Q13224 5/20 0.92
SIGMAR1 Q99720 3/20 0.92
PRCP P42785 3/20 0.92
GRIN2D O15399 1/20 0.92
GRIN3B O60391 1/20 0.92
CYP2B6 P20813 1/20 0.92
SLC6A2 P23975 1/20 0.92
SLC6A4 P31645 1/20 0.92
SLC6A3 Q01959 1/20 0.92
KCNH2 Q12809 1/20 0.92
GRIN2C Q14957 1/20 0.92
GRIN3A Q8TCU5 1/20 0.92
OPRM1 P35372 4/20 0.89
OPRD1 P41143 1/20 0.89
SLC6A9 P48067 3/20 0.54
OPRL1 P41146 2/20 0.54
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9153279 0.96 SIGMAR1 (1.00) GRIN1GRIN2AGRIN2BSIGMAR1PRCP
Phencyclidine SCHEMBL17008793 0.96 SIGMAR1 (1.00) GRIN1GRIN2AGRIN2BSIGMAR1PRCP
Phencyclidine SCHEMBL42022 0.96 SIGMAR1 (1.00) GRIN1GRIN2AGRIN2BSIGMAR1PRCP
Rolicyclidine SCHEMBL517928 0.96 SIGMAR1 (1.00) GRIN1GRIN2AGRIN2BSIGMAR1PRCP
Phencyclidine SCHEMBL21777 0.94 OPRM1 (1.00) GRIN1GRIN2AGRIN2BSIGMAR1PRCP
Phencyclidine SCHEMBL5166553 0.94 SIGMAR1 (0.96) GRIN1GRIN2AGRIN2BSIGMAR1PRCP
Phencyclidine SCHEMBL9431514 0.92 SIGMAR1 (0.92) GRIN1GRIN2AGRIN2BSIGMAR1PRCP
SCHEMBL30364176 0.91 SIGMAR1 (0.77) GRIN1GRIN2AGRIN2BSIGMAR1PRCP
SCHEMBL28282384 0.89 GRIN1 (0.88) GRIN1GRIN2AGRIN2BSIGMAR1PRCP
Phencyclidine SCHEMBL28296317 0.89 GRIN1 (0.86) GRIN1GRIN2AGRIN2BSIGMAR1PRCP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023154450-A2 (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2023-08-17 WO disclosed
US-20220409555-A1 ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS GILGAMESH PHARMACEUTICALS INC (US) 2022-12-29 US disclosed
US-11344510-B2 Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders GILGAMESH PHARMACEUTICALS, INC. (US) 2022-05-31 US disclosed
WO-2021134086-A1 ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2021-07-01 WO disclosed
WO-2020120539-A1 NEW PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS ESTEVE PHARMACEUTICALS, S.A. (ES) 2020-06-18 WO disclosed
US-8288430-B2 Spiro(5.5)undecane derivatives GRUNENTHAL GMBH (DE) 2012-10-16 US disclosed
EP-2257526-B1 SPIRO(5.5)UNDECANE DERIVATIVES GRUENENTHAL GMBH (DE) 2011-12-14 EP disclosed
EP-2257526-A1 SPIRO(5.5)UNDECANE DERIVATIVES Grünenthal GmbH (DE) 2010-12-08 EP disclosed
WO-2009118169-A1 SPIRO(5.5)UNDECANE DERIVATIVES Grünenthal GmbH (DE) 2009-10-01 WO disclosed
US-20090247505-A1 SPIRO(5.5)UNDECANE DERIVATIVES GRUNENTHAL GMBH (DE) 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11344510-B2 Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders HTR2C, PNMT, HTR2A GRIN1 83/4885GRIN2A 19/4885GRIN2B 33/4885
US-20220409555-A1 ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS HTR2C, PNMT, HTR2A GRIN1 75/4885GRIN2A 14/4885GRIN2B 26/4885
US-20090247505-A1 SPIRO(5.5)UNDECANE DERIVATIVES OPRL1, OPRD1, OPRM1 GRIN1 89/4885GRIN2A 157/4885GRIN2B 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.